Clinical Perspectives - Biologics in IBD: What's All the Fuss?
Up until the present time, agents with relatively nonspecific anti-inflammatory or immunomodulatory effects such as 5-acetylsalicylic acid, corticosteroids and azathioprine have been the mainstay of inflammatory bowel disease medical therapy. These drugs have been quite useful in one or more clinica...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2001-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2001/605398 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554436103241728 |
|---|---|
| author | Hillary Steinhart |
| author_facet | Hillary Steinhart |
| author_sort | Hillary Steinhart |
| collection | DOAJ |
| description | Up until the present time, agents with relatively nonspecific anti-inflammatory or immunomodulatory effects such as 5-acetylsalicylic acid, corticosteroids and azathioprine have been the mainstay of inflammatory bowel disease medical therapy. These drugs have been quite useful in one or more clinical settings, but they have been hampered by modest efficacy, significant toxicity or both. With greater understanding of the specific pathways of the gut mucosal immune response, it is hoped that newer biologic response modifiers will provide better efficacy, with an improved adverse event profile compared with older existing therapies. This article examines the evidence behind the use of biologic therapies such as anti-tumour necrosis factor-alpha, interleukin-10, interleukin-11, anti-integrin antibody and antisense intercellular adhesion molecule-1 oligonucleotide. |
| format | Article |
| id | doaj-art-8d024dc5ef61434894ad08d1485b3b2f |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2001-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-8d024dc5ef61434894ad08d1485b3b2f2025-02-03T05:51:37ZengWileyCanadian Journal of Gastroenterology0835-79002001-01-01151279980410.1155/2001/605398Clinical Perspectives - Biologics in IBD: What's All the Fuss?Hillary Steinhart0Department of Medicine, University of Toronto, Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, CanadaUp until the present time, agents with relatively nonspecific anti-inflammatory or immunomodulatory effects such as 5-acetylsalicylic acid, corticosteroids and azathioprine have been the mainstay of inflammatory bowel disease medical therapy. These drugs have been quite useful in one or more clinical settings, but they have been hampered by modest efficacy, significant toxicity or both. With greater understanding of the specific pathways of the gut mucosal immune response, it is hoped that newer biologic response modifiers will provide better efficacy, with an improved adverse event profile compared with older existing therapies. This article examines the evidence behind the use of biologic therapies such as anti-tumour necrosis factor-alpha, interleukin-10, interleukin-11, anti-integrin antibody and antisense intercellular adhesion molecule-1 oligonucleotide.http://dx.doi.org/10.1155/2001/605398 |
| spellingShingle | Hillary Steinhart Clinical Perspectives - Biologics in IBD: What's All the Fuss? Canadian Journal of Gastroenterology |
| title | Clinical Perspectives - Biologics in IBD: What's All the Fuss? |
| title_full | Clinical Perspectives - Biologics in IBD: What's All the Fuss? |
| title_fullStr | Clinical Perspectives - Biologics in IBD: What's All the Fuss? |
| title_full_unstemmed | Clinical Perspectives - Biologics in IBD: What's All the Fuss? |
| title_short | Clinical Perspectives - Biologics in IBD: What's All the Fuss? |
| title_sort | clinical perspectives biologics in ibd what s all the fuss |
| url | http://dx.doi.org/10.1155/2001/605398 |
| work_keys_str_mv | AT hillarysteinhart clinicalperspectivesbiologicsinibdwhatsallthefuss |